Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Publication | Closed Access

DOI

130

Citations

References

2024

Year

Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elías, Alejandro Acevedo, Jakub Cvek, Leslie M. Randall, Andrea Juliana Gomes,

The Lancet

Advanced Cervical CancerCervical Cancer ManagementCervical CancerMedicineGynecologyImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentPublic HealthOncologyRadiation OncologyGynecology OncologyOverall Survival Results